25 XP   0   0   10

Northwest Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyse Northwest Biotherapeutics Inc together

PenkeI guess you are interested in Northwest Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Northwest Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Northwest Biotherapeutics Inc

I send you an email if I find something interesting about Northwest Biotherapeutics Inc.

Quick analysis of Northwest Biotherapeutics Inc (30 sec.)










What can you expect buying and holding a share of Northwest Biotherapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.06
Expected worth in 1 year
$0.00
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$0.05
Return On Investment
11.1%

For what price can you sell your share?

Current Price per Share
$0.47
Expected price per share
$0.39 - $0.57
How sure are you?
50%

1. Valuation of Northwest Biotherapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.47

Intrinsic Value Per Share

$-0.51 - $-0.42

Total Value Per Share

$-0.57 - $-0.47

2. Growth of Northwest Biotherapeutics Inc (5 min.)




Is Northwest Biotherapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$65.7m-$108.8m$59.1m119.0%

How much money is Northwest Biotherapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$15.6m-$26.2m$10.6m67.8%
Net Profit Margin-4,306.6%-7,608.6%--

How much money comes from the company's main activities?

3. Financial Health of Northwest Biotherapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#987 / 1009

Most Revenue
#548 / 1009

Most Profit
#637 / 1009

Most Efficient
#894 / 1009

What can you expect buying and holding a share of Northwest Biotherapeutics Inc? (5 min.)

Welcome investor! Northwest Biotherapeutics Inc's management wants to use your money to grow the business. In return you get a share of Northwest Biotherapeutics Inc.

What can you expect buying and holding a share of Northwest Biotherapeutics Inc?

First you should know what it really means to hold a share of Northwest Biotherapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Northwest Biotherapeutics Inc is $0.4721. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Northwest Biotherapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Northwest Biotherapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.06. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Northwest Biotherapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.02-3.4%-0.01-2.8%-0.02-4.7%-0.02-4.8%-0.02-4.5%
Usd Book Value Change Per Share0.00-0.1%0.012.8%0.00-0.2%0.00-0.2%0.00-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-0.1%0.012.8%0.00-0.2%0.00-0.2%0.00-0.3%
Usd Price Per Share0.70-0.70-0.71-0.72-1.75-
Price to Earnings Ratio-11.01--13.47--8.90-13.61--3.09-
Price-to-Total Gains Ratio-1,273.67--375.19--1.89--45.73--407.95-
Price to Book Ratio-12.66--17.90--7.80--8.35--70.34-
Price-to-Total Gains Ratio-1,273.67--375.19--1.89--45.73--407.95-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.4721
Number of shares2118
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.00
Usd Total Gains Per Share0.010.00
Gains per Quarter (2118 shares)27.73-1.66
Gains per Year (2118 shares)110.94-6.63
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101111010-7-17
202222120-13-24
303333230-20-31
404444340-27-38
505555450-33-45
606666560-40-52
707777670-46-59
808888780-53-66
909989890-60-73
100110911000-66-80

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%8.032.00.020.0%10.041.040.011.0%
Book Value Change Per Share1.03.00.025.0%7.05.00.058.3%10.010.00.050.0%16.024.00.040.0%26.065.00.028.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%2.00.089.02.2%
Total Gains per Share1.03.00.025.0%7.05.00.058.3%10.010.00.050.0%16.024.00.040.0%26.065.00.028.6%

Fundamentals of Northwest Biotherapeutics Inc

About Northwest Biotherapeutics Inc

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Fundamental data was last updated by Penke on 2024-04-24 05:39:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Northwest Biotherapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Northwest Biotherapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Northwest Biotherapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -4,251.5% means that $-42.51 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Northwest Biotherapeutics Inc:

  • The MRQ is -4,251.5%. The company is making a huge loss. -2
  • The TTM is -4,306.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4,251.5%TTM-4,306.6%+55.1%
TTM-4,306.6%YOY-7,608.6%+3,302.0%
TTM-4,306.6%5Y-152,321.2%+148,014.7%
5Y-152,321.2%10Y-82,861.1%-69,460.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,251.5%-200.1%-4,051.4%
TTM-4,306.6%-216.8%-4,089.8%
YOY-7,608.6%-288.3%-7,320.3%
5Y-152,321.2%-449.1%-151,872.1%
10Y-82,861.1%-605.5%-82,255.6%
1.1.2. Return on Assets

Shows how efficient Northwest Biotherapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Northwest Biotherapeutics Inc to the Biotechnology industry mean.
  • -67.9% Return on Assets means that Northwest Biotherapeutics Inc generated $-0.68 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Northwest Biotherapeutics Inc:

  • The MRQ is -67.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -52.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-67.9%TTM-52.5%-15.4%
TTM-52.5%YOY-87.5%+35.0%
TTM-52.5%5Y-103.1%+50.6%
5Y-103.1%10Y-83.9%-19.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-67.9%-13.3%-54.6%
TTM-52.5%-12.8%-39.7%
YOY-87.5%-11.7%-75.8%
5Y-103.1%-13.9%-89.2%
10Y-83.9%-15.7%-68.2%
1.1.3. Return on Equity

Shows how efficient Northwest Biotherapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Northwest Biotherapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Northwest Biotherapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Northwest Biotherapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY--15.1%+15.1%
5Y--19.3%+19.3%
10Y--20.2%+20.2%

1.2. Operating Efficiency of Northwest Biotherapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Northwest Biotherapeutics Inc is operating .

  • Measures how much profit Northwest Biotherapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Northwest Biotherapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Northwest Biotherapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,099.6%+2,099.6%
TTM-2,099.6%YOY-7,184.8%+5,085.2%
TTM-2,099.6%5Y-151,795.1%+149,695.5%
5Y-151,795.1%10Y-82,081.6%-69,713.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM-2,099.6%-232.5%-1,867.1%
YOY-7,184.8%-298.2%-6,886.6%
5Y-151,795.1%-492.1%-151,303.0%
10Y-82,081.6%-632.4%-81,449.2%
1.2.2. Operating Ratio

Measures how efficient Northwest Biotherapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 35.03 means that the operating costs are $35.03 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Northwest Biotherapeutics Inc:

  • The MRQ is 35.027. The company is inefficient in keeping operating costs low. -1
  • The TTM is 59.659. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ35.027TTM59.659-24.632
TTM59.659YOY84.630-24.970
TTM59.6595Y450.758-391.099
5Y450.75810Y310.306+140.452
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ35.0273.231+31.796
TTM59.6593.310+56.349
YOY84.6303.890+80.740
5Y450.7585.739+445.019
10Y310.3067.876+302.430

1.3. Liquidity of Northwest Biotherapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Northwest Biotherapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.09 means the company has $0.09 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Northwest Biotherapeutics Inc:

  • The MRQ is 0.091. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.148. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.091TTM0.148-0.057
TTM0.148YOY0.080+0.068
TTM0.1485Y0.099+0.049
5Y0.09910Y0.111-0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0913.890-3.799
TTM0.1484.173-4.025
YOY0.0805.344-5.264
5Y0.0996.126-6.027
10Y0.1116.448-6.337
1.3.2. Quick Ratio

Measures if Northwest Biotherapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Northwest Biotherapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Northwest Biotherapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.044-0.044
TTM0.044YOY0.046-0.002
TTM0.0445Y0.053-0.009
5Y0.05310Y0.086-0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.514-3.514
TTM0.0443.998-3.954
YOY0.0465.380-5.334
5Y0.0536.105-6.052
10Y0.0866.404-6.318

1.4. Solvency of Northwest Biotherapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Northwest Biotherapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Northwest Biotherapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 3.36 means that Northwest Biotherapeutics Inc assets are financed with 336.0% credit (debt) and the remaining percentage (100% - 336.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Northwest Biotherapeutics Inc:

  • The MRQ is 3.360. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.666. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.360TTM2.666+0.695
TTM2.666YOY4.602-1.937
TTM2.6665Y6.107-3.442
5Y6.10710Y4.059+2.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3600.339+3.021
TTM2.6660.336+2.330
YOY4.6020.271+4.331
5Y6.1070.366+5.741
10Y4.0590.389+3.670
1.4.2. Debt to Equity Ratio

Measures if Northwest Biotherapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Northwest Biotherapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Northwest Biotherapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM-0.402-0.402
YOY-0.335-0.335
5Y-0.426-0.426
10Y-0.461-0.461

2. Market Valuation of Northwest Biotherapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Northwest Biotherapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Northwest Biotherapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -11.01 means the investor is paying $-11.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Northwest Biotherapeutics Inc:

  • The EOD is -7.424. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.007. Based on the earnings, the company is expensive. -2
  • The TTM is -13.468. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.424MRQ-11.007+3.584
MRQ-11.007TTM-13.468+2.461
TTM-13.468YOY-8.899-4.569
TTM-13.4685Y13.612-27.080
5Y13.61210Y-3.092+16.704
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.424-2.264-5.160
MRQ-11.007-2.629-8.378
TTM-13.468-2.680-10.788
YOY-8.899-4.145-4.754
5Y13.612-6.257+19.869
10Y-3.092-6.254+3.162
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Northwest Biotherapeutics Inc:

  • The EOD is -8.083. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.985. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -14.757. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.083MRQ-11.985+3.902
MRQ-11.985TTM-14.757+2.773
TTM-14.757YOY-15.560+0.803
TTM-14.7575Y-18.823+4.065
5Y-18.82310Y-32.538+13.715
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.083-2.973-5.110
MRQ-11.985-3.333-8.652
TTM-14.757-3.553-11.204
YOY-15.560-5.605-9.955
5Y-18.823-8.376-10.447
10Y-32.538-8.865-23.673
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Northwest Biotherapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -12.66 means the investor is paying $-12.66 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Northwest Biotherapeutics Inc:

  • The EOD is -8.541. Based on the equity, the company is expensive. -2
  • The MRQ is -12.664. Based on the equity, the company is expensive. -2
  • The TTM is -17.896. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.541MRQ-12.664+4.123
MRQ-12.664TTM-17.896+5.231
TTM-17.896YOY-7.805-10.091
TTM-17.8965Y-8.348-9.548
5Y-8.34810Y-70.342+61.993
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.5411.896-10.437
MRQ-12.6642.115-14.779
TTM-17.8962.093-19.989
YOY-7.8052.884-10.689
5Y-8.3483.542-11.890
10Y-70.3423.916-74.258
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Northwest Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0010.013-104%-0.001+57%-0.001+42%-0.001+148%
Book Value Per Share---0.055-0.042-24%-0.091+65%-0.112+103%-0.072+31%
Current Ratio--0.0910.148-38%0.080+14%0.099-8%0.111-17%
Debt To Asset Ratio--3.3602.666+26%4.602-27%6.107-45%4.059-17%
Debt To Equity Ratio----0%-0%-0%-0%
Dividend Per Share----0%-0%-0%-0%
Eps---0.016-0.013-16%-0.022+39%-0.023+43%-0.021+33%
Free Cash Flow Per Share---0.015-0.012-18%-0.012-20%-0.010-34%-0.012-20%
Free Cash Flow To Equity Per Share---0.002-0.001-64%-0.003+16%-0.001-62%-0.002-24%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.418--------
Intrinsic Value_10Y_min---0.513--------
Intrinsic Value_1Y_max---0.044--------
Intrinsic Value_1Y_min---0.048--------
Intrinsic Value_3Y_max---0.130--------
Intrinsic Value_3Y_min---0.148--------
Intrinsic Value_5Y_max---0.215--------
Intrinsic Value_5Y_min---0.251--------
Market Cap561784859.661-48%832979033.600835953958.7200%838928883.840-1%854499641.918-3%2085859823.113-60%
Net Profit Margin---42.515-43.066+1%-76.086+79%-1523.212+3483%-828.611+1849%
Operating Margin----20.9960%-71.8480%-1517.9510%-820.8160%
Operating Ratio--35.02759.659-41%84.630-59%450.758-92%310.306-89%
Pb Ratio-8.541+33%-12.664-17.896+41%-7.805-38%-8.348-34%-70.342+455%
Pe Ratio-7.424+33%-11.007-13.468+22%-8.899-19%13.612-181%-3.092-72%
Price Per Share0.472-48%0.7000.7030%0.705-1%0.718-3%1.753-60%
Price To Free Cash Flow Ratio-8.083+33%-11.985-14.757+23%-15.560+30%-18.823+57%-32.538+171%
Price To Total Gains Ratio-858.998+33%-1273.668-375.187-71%-1.892-100%-45.725-96%-407.950-68%
Quick Ratio---0.044-100%0.046-100%0.053-100%0.086-100%
Return On Assets---0.679-0.525-23%-0.875+29%-1.031+52%-0.839+24%
Return On Equity----0%-0%-0%-0%
Total Gains Per Share---0.0010.013-104%-0.001+57%-0.001+42%-0.001+148%
Usd Book Value---65773000.000-49691750.000-24%-108849500.000+65%-133211050.000+103%-86002800.000+31%
Usd Book Value Change Per Share---0.0010.013-104%-0.001+57%-0.001+42%-0.001+148%
Usd Book Value Per Share---0.055-0.042-24%-0.091+65%-0.112+103%-0.072+31%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.016-0.013-16%-0.022+39%-0.023+43%-0.021+33%
Usd Free Cash Flow---17376000.000-14268500.000-18%-13919250.000-20%-11399350.000-34%-13911200.000-20%
Usd Free Cash Flow Per Share---0.015-0.012-18%-0.012-20%-0.010-34%-0.012-20%
Usd Free Cash Flow To Equity Per Share---0.002-0.001-64%-0.003+16%-0.001-62%-0.002-24%
Usd Market Cap561784859.661-48%832979033.600835953958.7200%838928883.840-1%854499641.918-3%2085859823.113-60%
Usd Price Per Share0.472-48%0.7000.7030%0.705-1%0.718-3%1.753-60%
Usd Profit---18919000.000-15649750.000-17%-26258000.000+39%-26931100.000+42%-24453700.000+29%
Usd Revenue--445000.000483000.000-8%420750.000+6%433550.000+3%330875.000+34%
Usd Total Gains Per Share---0.0010.013-104%-0.001+57%-0.001+42%-0.001+148%
 EOD+2 -6MRQTTM+3 -27YOY+21 -95Y+18 -1210Y+17 -13

3.2. Fundamental Score

Let's check the fundamental score of Northwest Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.424
Price to Book Ratio (EOD)Between0-1-8.541
Net Profit Margin (MRQ)Greater than0-42.515
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.091
Debt to Asset Ratio (MRQ)Less than13.360
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.679
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Northwest Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.262
Ma 20Greater thanMa 500.522
Ma 50Greater thanMa 1000.538
Ma 100Greater thanMa 2000.605
OpenGreater thanClose0.499
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets27,865
Total Liabilities93,638
Total Stockholder Equity-65,773
 As reported
Total Liabilities 93,638
Total Stockholder Equity+ -65,773
Total Assets = 27,865

Assets

Total Assets27,865
Total Current Assets4,125
Long-term Assets23,740
Total Current Assets
Cash And Cash Equivalents 2,126
Other Current Assets 1,999
Total Current Assets  (as reported)4,125
Total Current Assets  (calculated)4,125
+/-0
Long-term Assets
Property Plant Equipment 21,461
Goodwill 626
Intangible Assets 1,292
Long-term Assets Other 361
Long-term Assets  (as reported)23,740
Long-term Assets  (calculated)23,740
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities45,204
Long-term Liabilities48,434
Total Stockholder Equity-65,773
Total Current Liabilities
Short Long Term Debt 20,480
Accounts payable 13,788
Other Current Liabilities 1,434
Total Current Liabilities  (as reported)45,204
Total Current Liabilities  (calculated)35,702
+/- 9,502
Long-term Liabilities
Long term Debt 20,312
Capital Lease Obligations Min Short Term Debt4,768
Long-term Liabilities Other 4,950
Long-term Liabilities  (as reported)48,434
Long-term Liabilities  (calculated)30,030
+/- 18,404
Total Stockholder Equity
Total Stockholder Equity (as reported)-65,773
Total Stockholder Equity (calculated)0
+/- 65,773
Other
Capital Stock1,175
Common Stock Shares Outstanding 1,175,459
Net Debt 38,666
Net Invested Capital -24,981
Net Working Capital -41,079
Property Plant and Equipment Gross 25,317



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302000-12-31
> Total Assets 
4,629
9,321
19,476
15,605
12,029
8,534
7,572
5,463
2,434
1,385
871
709
757
434
558
362
414
535
631
3,162
2,716
861
504
337
26,033
17,327
8,706
3,499
3,069
1,939
1,480
1,678
196
236
103
139
436
286
294
1,183
6,825
1,893
212
226
1,018
428
7,570
521
2,437
7,635
18,784
12,512
12,576
29,394
58,441
49,413
64,248
51,639
70,797
62,226
51,609
48,942
52,906
48,312
47,383
49,748
48,907
49,778
48,476
46,334
24,667
24,470
14,704
10,145
9,129
9,183
14,906
27,213
32,899
32,460
28,767
28,221
40,160
30,658
27,521
31,098
31,323
32,871
28,438
31,492
27,865
27,86531,49228,43832,87131,32331,09827,52130,65840,16028,22128,76732,46032,89927,21314,9069,1839,12910,14514,70424,47024,66746,33448,47649,77848,90749,74847,38348,31252,90648,94251,60962,22670,79751,63964,24849,41358,44129,39412,57612,51218,7847,6352,4375217,5704281,0182262121,8936,8251,1832942864361391032361961,6781,4801,9393,0693,4998,70617,32726,0333375048612,7163,1626315354143625584347577098711,3852,4345,4637,5728,53412,02915,60519,4769,3214,629
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,771
1,813
118
116
885
297
7,458
412
2,348
7,495
18,646
12,377
12,444
1,570
14,642
4,715
21,201
7,089
24,101
13,499
4,499
2,272
7,884
3,155
819
2,128
1,402
1,129
2,435
1,118
23,798
18,581
8,906
4,572
3,200
3,608
8,217
12,183
15,511
13,217
8,349
6,309
17,290
9,269
7,178
11,764
9,425
9,491
4,642
8,452
4,125
4,1258,4524,6429,4919,42511,7647,1789,26917,2906,3098,34913,21715,51112,1838,2173,6083,2004,5728,90618,58123,7981,1182,4351,1291,4022,1288193,1557,8842,2724,49913,49924,1017,08921,2014,71514,6421,57012,44412,37718,6467,4952,3484127,4582978851161181,8136,7710000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
25,393
16,875
7,861
2,578
1,205
23
16
566
50
115
65
94
180
80
153
1,068
6,702
1,643
24
37
430
111
7,346
373
1,985
7,357
18,499
12,230
12,267
1,403
14,255
4,049
20,223
6,139
22,699
12,434
3,026
1,487
6,871
2,232
22
1,051
117
198
1,597
248
22,224
16,288
6,676
1,970
372
764
5,955
9,250
9,983
7,468
3,758
3,836
15,169
6,963
4,831
9,425
6,965
6,191
1,424
6,097
2,126
2,1266,0971,4246,1916,9659,4254,8316,96315,1693,8363,7587,4689,9839,2505,9557643721,9706,67616,28822,2242481,5971981171,051222,2326,8711,4873,02612,43422,6996,13920,2234,04914,2551,40312,26712,23018,4997,3571,9853737,34611143037241,6436,7021,0681538018094651155056616231,2052,5787,86116,87525,3931100000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
0
0
3,414
0
865
879
1,021
747
886
746
883
685
685
397
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000003976856858837468867471,02187986503,414004,5000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
195
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000019500000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
54
80
94
110
133
131
112
109
89
140
138
135
132
27,824
43,799
44,698
43,047
44,550
46,696
48,727
47,110
46,670
45,022
45,157
46,564
47,620
47,505
48,649
46,041
45,216
869
5,889
5,798
5,573
5,929
5,575
6,689
15,030
17,388
19,243
20,418
21,912
22,870
21,389
20,343
19,334
21,898
23,380
23,796
23,040
23,740
23,74023,04023,79623,38021,89819,33420,34321,38922,87021,91220,41819,24317,38815,0306,6895,5755,9295,5735,7985,88986945,21646,04148,64947,50547,62046,56445,15745,02246,67047,11048,72746,69644,55043,04744,69843,79927,824132135138140891091121311331109480540000000000000000000000000000000000000000
       Property Plant Equipment 
2,768
2,677
2,785
2,783
3,054
2,966
1,348
1,286
397
402
373
336
299
186
118
94
79
67
53
43
34
24
15
16
9
12
19
124
237
248
394
396
7
7
0
0
39
39
39
39
38
64
78
76
100
98
95
92
89
140
83
80
77
23,914
39,999
41,386
41,999
43,965
46,157
48,360
46,892
46,550
315
261
224
188
169
48,568
45,980
45,149
108
277
355
365
281
317
157
819
1,040
1,234
1,312
1,264
15,027
14,385
13,748
17,077
19,635
21,100
21,517
20,765
21,461
21,46120,76521,51721,10019,63517,07713,74814,38515,0271,2641,3121,2341,04081915731728136535527710845,14945,98048,56816918822426131546,55046,89248,36046,15743,96541,99941,38639,99923,9147780831408992959810076786438393939390077396394248237124191291615243443536779941181862993363734023971,2861,3482,9663,0542,7832,7852,6772,768
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
654
626
626
626
626
626
626
626
626
626
626
626
626
626
62662662662662662662662662662662662662665400000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,292
1,292
1,292
1,292
1,292
1,292
1,292
1,292
1,292
1,292
1,292
1,292
1,292
1,292
1,2921,2921,2921,2921,2921,2921,2921,2921,2921,2921,2921,2921,2921,29200000000000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16
16
16
34
33
33
17
17
0
0
55
55
55
3,910
3,800
3,312
1,048
585
539
367
218
120
44,707
44,896
46,340
47,432
47,336
81
61
67
761
5,612
5,443
5,208
5,648
5,258
6,532
12,265
14,430
16,091
17,188
18,730
5,925
5,086
4,677
4,290
345
7,892
4,592
357
361
3613574,5927,8923454,2904,6775,0865,92518,73017,18816,09114,43012,2656,5325,2585,6485,2085,4435,61276167618147,33647,43246,34044,89644,7071202183675395851,0483,3123,8003,9105555550017173333341616160000000000000000000000000000000000000000
> Total Liabilities 
6,207
4,892
2,541
1,610
2,343
2,214
2,696
1,813
802
871
855
1,401
1,462
5,124
5,775
6,822
8,110
10,012
12,049
22,055
4,815
4,770
6,453
8,234
10,771
6,761
2,899
2,267
6,534
10,554
13,780
17,109
18,933
18,452
20,789
21,252
21,587
23,223
27,978
34,948
51,975
48,043
52,385
25,045
31,676
38,532
12,626
17,555
18,674
21,942
19,689
43,572
42,448
60,614
93,468
120,112
140,419
108,995
75,473
68,419
70,582
53,964
79,405
84,953
82,626
92,581
96,200
112,803
112,266
93,473
71,826
82,966
67,711
64,680
52,696
44,175
96,223
239,641
395,847
385,660
378,609
329,954
164,151
151,183
119,187
126,202
159,426
65,097
64,087
96,611
93,638
93,63896,61164,08765,097159,426126,202119,187151,183164,151329,954378,609385,660395,847239,64196,22344,17552,69664,68067,71182,96671,82693,473112,266112,80396,20092,58182,62684,95379,40553,96470,58268,41975,473108,995140,419120,11293,46860,61442,44843,57219,68921,94218,67417,55512,62638,53231,67625,04552,38548,04351,97534,94827,97823,22321,58721,25220,78918,45218,93317,10913,78010,5546,5342,2672,8996,76110,7718,2346,4534,7704,81522,05512,04910,0128,1106,8225,7755,1241,4621,4018558718021,8132,6962,2142,3431,6102,5414,8926,207
   > Total Current Liabilities 
5,345
4,421
2,186
1,233
1,898
1,759
1,649
1,048
733
751
740
1,302
1,375
5,052
5,763
6,815
8,105
10,008
12,046
22,054
4,815
4,770
6,453
8,234
10,771
6,761
2,899
2,267
6,534
10,554
13,780
16,422
18,237
17,595
19,430
19,978
19,944
19,801
26,124
33,326
50,893
46,145
50,752
23,949
30,333
36,153
10,744
16,239
18,674
17,220
19,689
43,572
42,448
43,297
68,880
90,968
116,546
87,247
64,789
57,806
59,899
53,964
76,405
81,906
72,790
81,134
87,683
103,687
98,546
77,276
69,840
74,216
55,464
53,423
41,194
39,659
88,570
226,276
382,424
363,409
360,708
312,321
133,769
130,012
98,158
116,128
126,005
44,708
39,925
49,223
45,204
45,20449,22339,92544,708126,005116,12898,158130,012133,769312,321360,708363,409382,424226,27688,57039,65941,19453,42355,46474,21669,84077,27698,546103,68787,68381,13472,79081,90676,40553,96459,89957,80664,78987,247116,54690,96868,88043,29742,44843,57219,68917,22018,67416,23910,74436,15330,33323,94950,75246,14550,89333,32626,12419,80119,94419,97819,43017,59518,23716,42213,78010,5546,5342,2672,8996,76110,7718,2346,4534,7704,81522,05412,04610,0088,1056,8155,7635,0521,3751,3027407517331,0481,6491,7591,8981,2332,1864,4215,345
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,995
6,355
11,569
13,248
18,948
19,776
1,990
2,101
2,277
1,601
1,222
1,172
32,250
29,220
45,914
68,253
93,888
57,192
29,101
15,576
11,646
21,285
30,813
39,372
26,898
25,965
61,962
76,311
71,092
44,796
44,413
55,698
41,216
37,889
25,714
22,859
68,501
199,413
357,409
344,106
340,323
290,532
113,888
110,600
75,544
93,682
0
11,916
9,486
0
0
009,48611,916093,68275,544110,600113,888290,532340,323344,106357,409199,41368,50122,85925,71437,88941,21655,69844,41344,79671,09276,31161,96225,96526,89839,37230,81321,28511,64615,57629,10157,19293,88868,25345,91429,22032,2501,1721,2221,6012,2772,1011,99019,77618,94813,24811,5696,3556,9950000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,711
25,268
32,026
4,775
11,361
11,925
6,639
4,859
135
14,046
8,599
7,003
6,135
12,316
12,879
10,166
6,267
2,374
7,655
8,074
7,239
12,117
9,993
20,167
15,538
10,606
10,261
21,899
20,480
20,48021,89910,26110,60615,53820,1679,99312,1177,2398,0747,6552,3746,26710,16612,87912,3166,1357,0038,59914,0461354,8596,63911,92511,3614,77532,02625,26831,71100000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
886
579
1,342
502
721
537
497
208
235
109
128
268
334
339
1,453
1,816
2,338
3,301
3,796
3,947
3,150
3,216
3,345
3,878
4,289
192
1,007
1,094
1,357
4,002
4,076
5,924
7,162
7,875
9,577
9,412
10,115
9,658
13,362
12,822
15,494
15,145
5,993
7,420
11,332
16,359
8,165
14,138
16,397
12,106
9,779
7,376
10,198
12,294
16,766
16,515
16,458
23,855
18,485
25,080
31,714
26,479
39,392
36,334
18,319
18,503
14,136
13,227
18,748
22,392
15,899
15,381
5,950
6,670
6,414
7,173
7,774
9,171
7,380
7,471
8,162
9,271
6,976
7,726
8,370
8,237
17,642
11,892
12,107
17,047
13,788
13,78817,04712,10711,89217,6428,2378,3707,7266,9769,2718,1627,4717,3809,1717,7747,1736,4146,6705,95015,38115,89922,39218,74813,22714,13618,50318,31936,33439,39226,47931,71425,08018,48523,85516,45816,51516,76612,29410,1987,3769,77912,10616,39714,1388,16516,35911,3327,4205,99315,14515,49412,82213,3629,65810,1159,4129,5777,8757,1625,9244,0764,0021,3571,0941,0071924,2893,8783,3453,2163,1503,9473,7963,3012,3381,8161,4533393342681281092352084975377215021,342579886
       Other Current Liabilities 
578
835
779
665
1,102
1,147
659
510
341
594
526
845
662
2,866
1,046
989
883
936
1,557
10,459
1,144
770
601
720
1,363
1,326
1,892
1,173
1,108
1,340
2,203
2,489
2,925
3,070
3,203
3,192
3,446
3,439
4,662
11,007
28,404
24,645
33,190
3,281
53
18
589
1,083
1,088
3,513
8,688
35,024
31,733
1,783
6,200
6,200
6,200
6,200
17,203
17,150
16,539
6,200
6,200
6,200
27,573
36,666
11,585
14,149
8,706
10,088
9,528
3,137
8,298
8,864
9,066
9,627
12,295
17,692
17,635
11,832
12,223
12,518
12,905
11,686
14,244
14,209
83,803
20,900
18,332
1,026
1,434
1,4341,02618,33220,90083,80314,20914,24411,68612,90512,51812,22311,83217,63517,69212,2959,6279,0668,8648,2983,1379,52810,0888,70614,14911,58536,66627,5736,2006,2006,20016,53917,15017,2036,2006,2006,2006,2001,78331,73335,0248,6883,5131,0881,08358918533,28133,19024,64528,40411,0074,6623,4393,4463,1923,2033,0702,9252,4892,2031,3401,1081,1731,8921,3261,3637206017701,14410,4591,5579368839891,0462,8666628455265943415106591,1471,102665779835578
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,082
1,898
1,633
1,096
1,343
2,379
1,882
1,316
0
4,722
0
0
0
17,317
24,588
29,144
23,873
21,748
10,684
10,613
10,683
0
3,000
3,047
9,836
11,447
8,517
9,116
13,720
16,197
1,986
8,750
12,247
11,257
11,502
4,516
7,653
13,365
13,423
22,251
17,901
17,633
30,382
21,171
21,029
10,074
33,421
20,389
24,162
47,388
48,434
48,43447,38824,16220,38933,42110,07421,02921,17130,38217,63317,90122,25113,42313,3657,6534,51611,50211,25712,2478,7501,98616,19713,7209,1168,51711,4479,8363,0473,000010,68310,61310,68421,74823,87329,14424,58817,3170004,72201,3161,8822,3791,3431,0961,6331,8981,0820000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
937
1,713
1,633
1,096
1,343
2,379
1,882
1,316
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,836
11,447
0
0
13,720
16,197
0
4,001
7,557
6,652
6,588
0
3,173
8,708
8,507
16,691
12,395
12,342
25,156
16,163
16,455
5,942
0
16,019
15,743
0
0
0015,74316,01905,94216,45516,16325,15612,34212,39516,6918,5078,7083,17306,5886,6527,5574,001016,19713,7200011,4479,83600000000000000001,3161,8822,3791,3431,0961,6331,7139370000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-6,995
-6,355
-11,569
-13,248
-18,948
-19,776
-1,990
-2,101
-2,277
-1,601
-1,222
-1,172
-32,250
-29,220
-45,914
-68,253
-93,888
-57,192
-29,101
-15,576
-11,646
-21,285
-30,813
-39,372
-26,898
-25,965
-61,962
-76,311
-71,092
-44,796
-44,413
-50,679
-36,246
-32,993
-20,405
-17,959
-63,710
-194,516
-352,326
-338,376
-334,568
-284,936
-108,345
-105,267
-70,641
-89,216
4,724
-7,177
-4,732
4,503
4,768
4,7684,503-4,732-7,1774,724-89,216-70,641-105,267-108,345-284,936-334,568-338,376-352,326-194,516-63,710-17,959-20,405-32,993-36,246-50,679-44,413-44,796-71,092-76,311-61,962-25,965-26,898-39,372-30,813-21,285-11,646-15,576-29,101-57,192-93,888-68,253-45,914-29,220-32,250-1,172-1,222-1,601-2,277-2,101-1,990-19,776-18,948-13,248-11,569-6,355-6,9950000000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,017
11,017
11,017
10,777
8,913
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,798
20,514
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,746
0
23,752
25,385
0
0
0025,38523,752013,746000000000000000020,51417,79800000000000000008,91310,77711,01711,01711,0170000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
145
185
0
0
0
0
0
0
0
4,722
0
0
0
17,317
24,588
29,144
23,873
21,748
10,684
10,613
10,683
0
3,000
3,047
0
0
8,517
9,116
0
0
1,986
4,749
4,690
4,605
4,914
4,516
4,480
4,657
4,916
5,560
5,506
5,291
5,226
5,008
4,574
4,132
0
4,370
8,419
4,550
4,950
4,9504,5508,4194,37004,1324,5745,0085,2265,2915,5065,5604,9164,6574,4804,5164,9144,6054,6904,7491,986009,1168,517003,0473,000010,68310,61310,68421,74823,87329,14424,58817,3170004,72200000001851450000000000000000000000000000000000000000
> Total Stockholder Equity
0
4,429
16,935
13,995
9,686
6,320
4,876
3,650
1,632
514
16
0
0
0
0
0
0
0
0
0
0
0
0
0
15,262
10,566
5,807
1,232
0
0
0
0
0
0
0
0
0
0
0
0
-45,150
-46,150
-52,173
-24,819
-30,658
-38,104
-16,073
-28,051
-27,254
-25,084
-9,818
-31,060
-29,872
-31,220
-35,027
-70,699
-76,171
-57,356
-4,676
-6,193
-18,973
-5,022
-26,499
-36,641
-35,243
-42,833
-67,333
-80,823
-84,304
-47,139
-47,159
-58,496
-53,007
-54,535
-43,567
-34,992
-81,317
-212,428
-362,948
-353,200
-349,842
-301,733
-123,991
-120,525
-91,666
-108,850
-128,103
-55,978
-61,034
-65,119
-65,773
-65,773-65,119-61,034-55,978-128,103-108,850-91,666-120,525-123,991-301,733-349,842-353,200-362,948-212,428-81,317-34,992-43,567-54,535-53,007-58,496-47,159-47,139-84,304-80,823-67,333-42,833-35,243-36,641-26,499-5,022-18,973-6,193-4,676-57,356-76,171-70,699-35,027-31,220-29,872-31,060-9,818-25,084-27,254-28,051-16,073-38,104-30,658-24,819-52,173-46,150-45,1500000000000001,2325,80710,56615,2620000000000000165141,6323,6504,8766,3209,68613,99516,9354,4290
   Retained Earnings 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
239,684
239,202
-251,778
-261,929
-272,079
288,575
-319,098
-333,492
-345,086
-367,996
-384,887
-430,928
-456,793
-477,836
-520,521
-566,954
0
0
0
0
0
0
-715,476
-728,096
-738,349
-761,620
-788,619
-810,164
-831,341
-818,763
-824,413
-840,557
-840,338
-846,580
-839,907
-837,181
-895,133
-1,090,917
-1,371,216
-1,375,339
-1,370,929
-1,325,410
-1,192,090
-1,206,304
-1,235,972
-1,268,824
-1,297,122
-1,307,774
-1,322,222
-1,340,802
-1,359,721
-1,359,721-1,340,802-1,322,222-1,307,774-1,297,122-1,268,824-1,235,972-1,206,304-1,192,090-1,325,410-1,370,929-1,375,339-1,371,216-1,090,917-895,133-837,181-839,907-846,580-840,338-840,557-824,413-818,763-831,341-810,164-788,619-761,620-738,349-728,096-715,476000000-566,954-520,521-477,836-456,793-430,928-384,887-367,996-345,086-333,492-319,098288,575-272,079-261,929-251,778239,202239,6840000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
194,716
193,152
199,605
237,140
241,446
250,467
303,188
305,604
317,991
343,065
375,213
400,003
427,177
446,744
485,615
496,443
557,136
553,797
630,613
634,696
635,550
678,624
686,972
689,736
702,661
718,831
721,554
730,502
746,509
770,739
775,741
780,478
785,648
789,449
794,900
799,660
811,526
877,376
1,008,665
1,021,900
1,021,107
1,022,826
1,066,873
1,083,723
1,139,811
1,152,689
0
1,248,397
1,258,259
0
0
001,258,2591,248,39701,152,6891,139,8111,083,7231,066,8731,022,8261,021,1071,021,9001,008,665877,376811,526799,660794,900789,449785,648780,478775,741770,739746,509730,502721,554718,831702,661689,736686,972678,624635,550634,696630,613553,797557,136496,443485,615446,744427,177400,003375,213343,065317,991305,604303,188250,467241,446237,140199,605193,152194,7160000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,932
Cost of Revenue-0
Gross Profit01,932
 
Operating Income (+$)
Gross Profit0
Operating Expense-57,440
Operating Income-55,508-57,440
 
Operating Expense (+$)
Research Development27,730
Selling General Administrative29,710
Selling And Marketing Expenses0
Operating Expense57,44057,440
 
Net Interest Income (+$)
Interest Income0
Interest Expense-5,241
Other Finance Cost-0
Net Interest Income-5,241
 
Pretax Income (+$)
Operating Income-55,508
Net Interest Income-5,241
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-62,599-53,658
EBIT - interestExpense = -5,241
-62,599
-57,358
Interest Expense5,241
Earnings Before Interest and Taxes (EBIT)0-57,358
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-62,599
Tax Provision-0
Net Income From Continuing Ops-62,599-62,599
Net Income-62,599
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-1,8505,241
 

Technical Analysis of Northwest Biotherapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Northwest Biotherapeutics Inc. The general trend of Northwest Biotherapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Northwest Biotherapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Northwest Biotherapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.5 < 0.57 < 0.57.

The bearish price targets are: 0.47 > 0.4 > 0.39.

Tweet this
Northwest Biotherapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Northwest Biotherapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Northwest Biotherapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Northwest Biotherapeutics Inc. The current macd is -0.01625592.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Northwest Biotherapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Northwest Biotherapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Northwest Biotherapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Northwest Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartNorthwest Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Northwest Biotherapeutics Inc. The current adx is 17.28.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Northwest Biotherapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Northwest Biotherapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Northwest Biotherapeutics Inc. The current sar is 0.59948211.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Northwest Biotherapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Northwest Biotherapeutics Inc. The current rsi is 36.26. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Northwest Biotherapeutics Inc Daily Relative Strength Index (RSI) ChartNorthwest Biotherapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Northwest Biotherapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Northwest Biotherapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Northwest Biotherapeutics Inc Daily Stochastic Oscillator ChartNorthwest Biotherapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Northwest Biotherapeutics Inc. The current cci is -163.10859564.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Northwest Biotherapeutics Inc Daily Commodity Channel Index (CCI) ChartNorthwest Biotherapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Northwest Biotherapeutics Inc. The current cmo is -38.2432296.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Northwest Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartNorthwest Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Northwest Biotherapeutics Inc. The current willr is -91.06976744.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Northwest Biotherapeutics Inc Daily Williams %R ChartNorthwest Biotherapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Northwest Biotherapeutics Inc.

Northwest Biotherapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Northwest Biotherapeutics Inc. The current atr is 0.0366565.

Northwest Biotherapeutics Inc Daily Average True Range (ATR) ChartNorthwest Biotherapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Northwest Biotherapeutics Inc. The current obv is -149,154,175.

Northwest Biotherapeutics Inc Daily On-Balance Volume (OBV) ChartNorthwest Biotherapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Northwest Biotherapeutics Inc. The current mfi is 19.99.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Northwest Biotherapeutics Inc Daily Money Flow Index (MFI) ChartNorthwest Biotherapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Northwest Biotherapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Northwest Biotherapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Northwest Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.262
Ma 20Greater thanMa 500.522
Ma 50Greater thanMa 1000.538
Ma 100Greater thanMa 2000.605
OpenGreater thanClose0.499
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Northwest Biotherapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Northwest Biotherapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Northwest Biotherapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Northwest Biotherapeutics Inc

I send you an email if I find something interesting about Northwest Biotherapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Northwest Biotherapeutics Inc.

Receive notifications about Northwest Biotherapeutics Inc in your mailbox!